Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Three major studies support antiglaucoma efficacy of Cosopt

Nov. 19, 1998

Animal data suggest that GPI-1046 may be useful in glaucoma

Nov. 18, 1998

New prostaglandins with IOP-lowering effects disclosed by Santen and Asahi Glass

Nov. 16, 1998

Final results presented from phase II Vitrase trial

Nov. 13, 1998

Significant antiinflammatory activity seen with loteprednol etabonate in cataract surgery setting

Nov. 5, 1998

Vitrase to be fast-tracked by FDA

Oct. 16, 1998

Long-acting fluorine-containing prostaglandins for ocular diseases

Oct. 7, 1998

Phase II trial commences of AG-3340 in AMD

Sep. 17, 1998

Phase II testing of ISV-205 begins for glaucoma

Sep. 14, 1998

Micrologix Biotech advances development of antimicrobial peptides for treatment of eye infections

Sep. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.